Cogent Biosciences, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 275 WYMAN STREET, WALTHAM, MA, 02451
Mailing Address 275 WYMAN STREET, WALTHAM, MA, 02451
Phone 617-945-5576
Fiscal Year End 1231
EIN 465308248
Financial Overview
FY2025
-$255.86M
Net Income
$312.01M
Cash & Equivalents
$-2.16
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 17, 2026 | View on SEC |
| 10-K Annual financial report | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 30, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | January 22, 2026 | View on SEC |
| 4 Insider stock transaction report | January 22, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 21, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 21, 2026 | View on SEC |
Annual Reports
10-K February 17, 2026
- Clinical-stage biopharmaceutical company focused on precision treatments for diseases driven by genetic mutations, particularly in oncology.
- Lead program, Bezunide (CGT9486), is an investigational therapy for GIST and SM, progressing through clinical development.
Insider Trading
STRONG SELL 5 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.